Back to Search
Start Over
PIK3CAtesting in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories
- Source :
- Pharmacogenomics; March 2024, Vol. 25 Issue: 3 p161-169, 9p
- Publication Year :
- 2024
-
Abstract
- Introduction:PIK3CAgene mutations occur in approximately 40% of hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancers (MBCs), electing them to targeted therapy. Testing PIK3CAstatus is complex due to selection of biological specimen and testing method. Materials & methods:This work investigates real-life experience on PIK3CAtesting in HR+/HER2−MBC. Clinical, technical and molecular data on PIK3CAtesting were collected from two referral laboratories. Additionally, the results of a nationwide PIK3CAsurvey involving 116 institutions were assessed. Results:Overall, n = 35 MBCs were PIK3CA-mutated, with mutations mostly occurring in exons 9 (n = 19; 51.4%) and 20 (n = 15; 40.5%). The nationwide survey revealed significant variability across laboratories in terms of sampling methodology, technical assessment and clinical report signing healthcare figures for PIK3CAmolecular testing in diagnostic routine practice. Conclusion:This study provides insights into the real-world routine of PIK3CAtesting in HR+/HER2−MBC and highlights the need for standardization and networking in predictive pathology.
Details
- Language :
- English
- ISSN :
- 14622416 and 17448042
- Volume :
- 25
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- Pharmacogenomics
- Publication Type :
- Periodical
- Accession number :
- ejs65674086
- Full Text :
- https://doi.org/10.2217/pgs-2023-0238